that would not be a smart economic or health move ... right now it just sounds political, but I guess we will just have to see.
what i see right now ... probably like this for next cpl of weeks
Incyte Corporation (Nasdaq: INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1110PD) containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. These data will be highlighted in a poster discussion on Monday, 10 October 2016 from 11:00-12:00 CET at the ESMO Annual Congress 2016 in Copenhagen, Denmark.
In patients with treatment-naïve advanced melanoma (n=19), updated data show a disease control rate (DCR) of 74 percent and an overall response rate (ORR) of 58 percent. All responses are confirmed and ongoing (median follow-up 42 weeks); median progression-free survival (PFS) has not been reached.
its a great question ... stock vs options. if it proves out to be a bunch of rumours, TWTR will PB back to around $14 so for every 1000 shares i would stand to take a $7 K hit. for that same $7K risk, i can buy a ton of options on a bet (that is just the way i look at it).